{"nctId":"NCT00072384","briefTitle":"Systemic Chemotherapy and Subtenon Carboplatin, and Local Ophthalmic Therapy in Children With Intraocular Retinoblastoma","startDateStruct":{"date":"2007-04-16","type":"ACTUAL"},"conditions":["Intraocular Retinoblastoma"],"count":30,"armGroups":[{"label":"Treatment (chemotherapy, surgery)","type":"EXPERIMENTAL","interventionNames":["Drug: liposomal vincristine sulfate","Procedure: cryosurgery","Procedure: laser surgery","Drug: carboplatin","Drug: etoposide","Biological: filgrastim"]}],"interventions":[{"name":"liposomal vincristine sulfate","otherNames":["liposomal vincristine","Marqibo","vincristine liposomal","vincristine sulfate liposome injection"]},{"name":"cryosurgery","otherNames":["cryoablation","cryosurgical ablation"]},{"name":"laser surgery","otherNames":["conventional laser therapy","laser therapy, conventional","surgery, laser"]},{"name":"carboplatin","otherNames":["Carboplat","CBDCA","JM-8","Paraplat","Paraplatin"]},{"name":"etoposide","otherNames":["EPEG","VP-16","VP-16-213"]},{"name":"filgrastim","otherNames":["G-CSF","Neupogen"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of bilateral retinoblastoma with at least 1 eye group C or D intraocular retinoblastoma by ophthalmologic examination, defined by the International Classification System for Intraocular Retinoblastoma as the following:\n\n  * Group C: Discrete localized disease with minimal subretinal and/or vitreous seeding\n\n    * Subretinal fluid, without prior or concurrent seeding, involving ≤ one quarter of the retina\n    * Local fine vitreous seeding may be present close to discrete tumor\n    * Local subretinal seeding \\< 3 mm from tumor\n  * Group D: Diffuse disease with significant vitreous and/or subretinal seeding\n\n    * Tumor(s) may be massive or diffuse\n    * Subretinal fluid, without prior or concurrent seeding, involving up to total retinal detachment\n    * Diffuse or massive vitreous disease may include \"greasy\" seeds or avascular tumor masses\n    * Diffuse subretinal seeding may include subretinal plaques or tumor nodules\n* Prior enucleation of 1 eye allowed provided the remaining eye is group C or D\n* No tumor present on histologic examination at the cut end of the optic nerve on any eye enucleated prior to study entry\n\n  * Evidence of choroidal and/or optic nerve invasion past the lumina cribrosa is allowed\n* No extraocular retinoblastoma clinically or by MRI of brain and orbits with and without gadolinium or CT scan with and without contrast of brain and orbits\n* No evidence of systemic metastases by bone marrow, lumbar puncture, bone scan, and/or any other additional test\n* Performance status - Karnofsky 50-100% (over 16 years of age)\n* Performance status - Lansky 50-100% (16 and under)\n* Bilirubin ≤ 1.5 times upper limit of normal (ULN) for age\n* AST and ALT \\< 2.5 times ULN for age\n* Creatinine adjusted according to age as follows:\n\n  * No greater than 0.4 mg/dL (≤ 5 months)\n  * No greater than 0.5 mg/dL (6 months -11 months)\n  * No greater than 0.6 mg/dL (1 year-23 months)\n  * No greater than 0.8 mg/dL (2 years-5 years)\n  * No greater than 1.0 mg/dL (6 years-9 years)\n  * No greater than 1.2 mg/dL (10 years-12 years)\n  * No greater than 1.4 mg/dL (13 years and over \\[female\\])\n  * No greater than 1.5 mg/dL (13 years to 15 years \\[male\\])\n  * No greater than 1.7 mg/dL (16 years and over \\[male\\])\n* Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min/1.73m\\^2\n* Not pregnant or nursing\n* Fertile patients must use effective contraception\n* Negative pregnancy test in postmenarchal females\n* No prior chemotherapy\n* No other concurrent chemotherapy\n* No prior radiotherapy\n* No other concurrent radiotherapy","healthyVolunteers":false,"sex":"ALL","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Group D Eyes - Treatment Failure Within One Year","description":"Each Group D eye will be classified as experiencing failure within one year after start of treatment: yes or no. The method of Rosner et al. (Biometrics v. 38, 105-114, 1982) will be used to model possible dependence between eyes from the same patient. The point estimate of the probability of treatment failure is reported as the \"Mean\" measure type.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.52","spread":"0.102299"}]}]}]},{"type":"PRIMARY","title":"Group C Eyes - Treatment Failure Within One Year","description":"Each Group C eye will be classified as experiencing failure within one year after start of treatment: yes or no. The method of Rosner et al. (Biometrics v. 38, 105-114, 1982) will be used to model possible dependence between eyes from the same patient. The point estimate of the probability of treatment failure is reported as the \"Mean\" measure type.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"0.217"}]}]}]},{"type":"SECONDARY","title":"Event-free Survival (EFS)","description":"Proportion of patients event free at 1 year following enrollment. Event free survival time is computed as the time to study entry until disease relapse/progression, secondary malignancy, or death.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.45","spread":null}]}]}]},{"type":"SECONDARY","title":"Toxicity Associated With Chemotherapy","description":"The number of patients that experience CTC Version 4 grade 3 or higher toxicities of any kind.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Patterns of Failure for Group C and Group D in Terms of Vitreous vs Patterns of Failure for Group C and Group D in Terms of Vitreous vs Retinal vs Both as Sites of Recurrence","description":"Sites of disease recurrence for Group C and Group D eyes where treatment failure was detected","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Patterns of Treatment Failure vs. no Treatment Failure for Group C Eyes and Group D Eyes According to Initial Sites of Involvement","description":"The association between the probability of experiencing treatment failure vs. no failure in a C eye and the presence of subretinal seeding (SRS), subretinal fluid (SRF), or vitreal seeding (VS) at the on study ophthalmological examination under anesthesia. The association between the probability of experiencing treatment failure vs. no failure in a D eye and the presence of subretinal seeding (SRS), subretinal fluid (SRF), or vitreal seeding (VS) at the on study ophthalmological examination under anesthesia.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":22},"commonTop":["Neutrophil count decreased","Eye disorders - Other, specify","Hearing impaired","Infections and infestations - Other, specify","Anorectal infection"]}}}